NASDAQ:VACC

Vaccitech Competitors

$14.76
+0.01 (+0.07 %)
(As of 07/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.75
$15.16
50-Day Range
$13.90
$17.00
52-Week Range
$12.25
$17.99
Volume3,905 shs
Average Volume29,789 shs
Market Capitalization$506.71 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Vaccitech (NASDAQ:VACC) Vs. AXSM, LGND, CNTA, DCPH, ORGO, and MYOV

Should you be buying VACC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Vaccitech, including Axsome Therapeutics (AXSM), Ligand Pharmaceuticals (LGND), Centessa Pharmaceuticals (CNTA), Deciphera Pharmaceuticals (DCPH), Organogenesis (ORGO), and Myovant Sciences (MYOV).

Axsome Therapeutics (NASDAQ:AXSM) and Vaccitech (NASDAQ:VACC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Valuation & Earnings

This table compares Axsome Therapeutics and Vaccitech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome TherapeuticsN/AN/A$-102,900,000.00($2.74)-19.65
Vaccitech$4.82 million105.13$-17,710,000.00N/AN/A

Vaccitech has higher revenue and earnings than Axsome Therapeutics.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Axsome Therapeutics and Vaccitech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axsome Therapeutics10902.80
Vaccitech00403.00

Axsome Therapeutics currently has a consensus target price of $121.5963, indicating a potential upside of 122.13%. Vaccitech has a consensus target price of $25.00, indicating a potential upside of 69.38%. Given Axsome Therapeutics' higher probable upside, research analysts clearly believe Axsome Therapeutics is more favorable than Vaccitech.

Insider and Institutional Ownership

60.6% of Axsome Therapeutics shares are owned by institutional investors. 26.0% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Axsome Therapeutics and Vaccitech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axsome TherapeuticsN/A-78.81%-52.66%
VaccitechN/AN/AN/A

Summary

Vaccitech beats Axsome Therapeutics on 5 of the 9 factors compared between the two stocks.

Vaccitech (NASDAQ:VACC) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares Vaccitech and Ligand Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaccitech$4.82 million105.13$-17,710,000.00N/AN/A
Ligand Pharmaceuticals$186.42 million10.83$-2,980,000.00$3.1338.76

Ligand Pharmaceuticals has higher revenue and earnings than Vaccitech.

Analyst Ratings

This is a summary of current ratings and target prices for Vaccitech and Ligand Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaccitech00403.00
Ligand Pharmaceuticals01502.83

Vaccitech currently has a consensus price target of $25.00, indicating a potential upside of 69.38%. Ligand Pharmaceuticals has a consensus price target of $228.75, indicating a potential upside of 87.36%. Given Ligand Pharmaceuticals' higher probable upside, analysts clearly believe Ligand Pharmaceuticals is more favorable than Vaccitech.

Insider and Institutional Ownership

91.9% of Ligand Pharmaceuticals shares are owned by institutional investors. 10.6% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Vaccitech and Ligand Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaccitechN/AN/AN/A
Ligand Pharmaceuticals18.83%8.50%4.70%

Summary

Ligand Pharmaceuticals beats Vaccitech on 9 of the 11 factors compared between the two stocks.

Vaccitech (NASDAQ:VACC) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares Vaccitech and Centessa Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaccitech$4.82 million105.13$-17,710,000.00N/AN/A
Centessa PharmaceuticalsN/AN/AN/AN/AN/A

Centessa Pharmaceuticals has lower revenue, but higher earnings than Vaccitech.

Analyst Ratings

This is a summary of current ratings and target prices for Vaccitech and Centessa Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaccitech00403.00
Centessa Pharmaceuticals00303.00

Vaccitech currently has a consensus price target of $25.00, indicating a potential upside of 69.38%. Centessa Pharmaceuticals has a consensus price target of $38.00, indicating a potential upside of 78.82%. Given Centessa Pharmaceuticals' higher probable upside, analysts clearly believe Centessa Pharmaceuticals is more favorable than Vaccitech.

Profitability

This table compares Vaccitech and Centessa Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaccitechN/AN/AN/A
Centessa PharmaceuticalsN/AN/AN/A

Summary

Vaccitech beats Centessa Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

Vaccitech (NASDAQ:VACC) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares Vaccitech and Deciphera Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaccitech$4.82 million105.13$-17,710,000.00N/AN/A
Deciphera Pharmaceuticals$42.09 million45.92$-266,490,000.00($4.78)-6.98

Vaccitech has higher earnings, but lower revenue than Deciphera Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and target prices for Vaccitech and Deciphera Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaccitech00403.00
Deciphera Pharmaceuticals01602.86

Vaccitech currently has a consensus price target of $25.00, indicating a potential upside of 69.38%. Deciphera Pharmaceuticals has a consensus price target of $70.50, indicating a potential upside of 111.84%. Given Deciphera Pharmaceuticals' higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than Vaccitech.

Insider and Institutional Ownership

73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. 4.1% of Deciphera Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Vaccitech and Deciphera Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaccitechN/AN/AN/A
Deciphera Pharmaceuticals-379.54%-45.63%-39.48%

Summary

Vaccitech beats Deciphera Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Vaccitech (NASDAQ:VACC) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares Vaccitech and Organogenesis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaccitech$4.82 million105.13$-17,710,000.00N/AN/A
Organogenesis$338.30 million5.69$17.95 million$0.1693.81

Organogenesis has higher revenue and earnings than Vaccitech.

Analyst Ratings

This is a summary of current ratings and target prices for Vaccitech and Organogenesis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaccitech00403.00
Organogenesis00403.00

Vaccitech currently has a consensus price target of $25.00, indicating a potential upside of 69.38%. Organogenesis has a consensus price target of $17.50, indicating a potential upside of 16.05%. Given Vaccitech's higher probable upside, equities research analysts clearly believe Vaccitech is more favorable than Organogenesis.

Insider and Institutional Ownership

19.4% of Organogenesis shares are owned by institutional investors. 57.2% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Vaccitech and Organogenesis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaccitechN/AN/AN/A
Organogenesis11.66%43.70%16.42%

Summary

Organogenesis beats Vaccitech on 7 of the 9 factors compared between the two stocks.

Vaccitech (NASDAQ:VACC) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Valuation & Earnings

This table compares Vaccitech and Myovant Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaccitech$4.82 million105.13$-17,710,000.00N/AN/A
Myovant Sciences$59.32 million32.15$-255,130,000.00($2.83)-7.37

Vaccitech has higher earnings, but lower revenue than Myovant Sciences.

Analyst Recommendations

This is a summary of current ratings and price targets for Vaccitech and Myovant Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaccitech00403.00
Myovant Sciences03202.40

Vaccitech presently has a consensus price target of $25.00, indicating a potential upside of 69.38%. Myovant Sciences has a consensus price target of $28.40, indicating a potential upside of 34.03%. Given Vaccitech's stronger consensus rating and higher probable upside, research analysts plainly believe Vaccitech is more favorable than Myovant Sciences.

Insider & Institutional Ownership

31.7% of Myovant Sciences shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Vaccitech and Myovant Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaccitechN/AN/AN/A
Myovant SciencesN/AN/A-57.93%

Summary

Vaccitech beats Myovant Sciences on 6 of the 9 factors compared between the two stocks.


Vaccitech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.9$53.84+3.8%$2.02 billionN/A-20.24Unusual Options Activity
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$121.31+0.8%$2.02 billion$186.42 million52.74Upcoming Earnings
News Coverage
CNTA
Centessa Pharmaceuticals
1.7$21.64+2.3%$1.95 billionN/A0.00
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$33.35+0.2%$1.93 billion$42.09 million-7.43
Organogenesis logo
ORGO
Organogenesis
1.6$15.01+0.7%$1.92 billion$338.30 million41.70Insider Selling
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$20.85+0.4%$1.91 billion$59.32 million-7.37Upcoming Earnings
Analyst Downgrade
Nuvation Bio logo
NUVB
Nuvation Bio
1.7$8.60+0.3%$1.87 billionN/A-37.39Analyst Downgrade
Xencor logo
XNCR
Xencor
1.6$32.00+1.1%$1.86 billion$122.69 million-28.83
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$28.71+2.5%$1.79 billion$123.80 million-7.11Unusual Options Activity
News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.6$29.09+1.0%$1.66 billion$159.74 million138.52
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.8$34.72+15.7%$1.63 billionN/A-7.61Analyst Upgrade
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.6$35.31+2.3%$1.63 billion$38.95 million-9.27Analyst Downgrade
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.0$33.99+0.0%$1.63 billionN/A-11.18
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$20.98+1.0%$1.62 billion$87.37 million-13.36Analyst Upgrade
News Coverage
Gap Up
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.1$35.87+4.8%$1.62 billionN/A-14.95Insider Selling
News Coverage
Amarin logo
AMRN
Amarin
1.7$4.02+2.5%$1.59 billion$614.06 million-80.40
Avid Bioservices logo
CDMO
Avid Bioservices
1.5$25.96+1.4%$1.59 billion$95.87 million649.16
MacroGenics logo
MGNX
MacroGenics
2.0$25.64+1.8%$1.54 billion$104.88 million-10.34Upcoming Earnings
Analyst Downgrade
Insider Selling
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$34.90+0.7%$1.52 billion$20.75 million-22.23Insider Selling
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$21.73+1.4%$1.50 billion$2.34 million-5.87Analyst Downgrade
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$88.98+2.2%$1.48 billionN/A-6.32
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$11.36+1.8%$1.46 billion$50.12 million-11.47
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$4.84+0.6%$1.46 billion$1.99 billion-40.33
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.7$36.45+1.2%$1.46 billionN/A-10.27Analyst Upgrade
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
2.3$27.34+0.1%$1.45 billion$520.40 million13.21Analyst Downgrade
News Coverage
CNTB
Connect Biopharma
1.5$25.00+1.8%$1.44 billionN/A0.00
PureTech Health logo
PRTC
PureTech Health
1.3$48.00+2.6%$1.38 billion$11.77 million2,400.00Gap Up
Innoviva logo
INVA
Innoviva
1.4$13.40+0.1%$1.36 billion$336.79 million5.90
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
1.8$30.45+0.8%$1.35 billion$17.82 million-13.07
DAWN
Day One Biopharmaceuticals
1.7$22.33+0.6%$1.35 billionN/A0.00
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$12.98+0.5%$1.32 billion$88.64 million-5.17
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
1.7$33.76+3.6%$1.29 billionN/A-13.24Insider Selling
Short Interest Increase
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.3$29.64+1.5%$1.29 billion$54.13 million-8.17
Kura Oncology logo
KURA
Kura Oncology
1.2$18.57+0.0%$1.23 billionN/A-10.73
Kronos Bio logo
KRON
Kronos Bio
1.9$21.87+0.3%$1.23 billionN/A-5.83News Coverage
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.7$33.12+1.2%$1.23 billion$140,000.00-8.69
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.7$24.36+2.4%$1.22 billionN/A-6.96Analyst Downgrade
Gap Down
FibroGen logo
FGEN
FibroGen
1.6$13.27+2.8%$1.22 billion$176.32 million-6.57Analyst Downgrade
JANX
Janux Therapeutics
1.3$30.36+0.0%$1.21 billionN/A0.00Quiet Period Expiration
uniQure logo
QURE
uniQure
1.8$26.04+1.7%$1.20 billion$37.51 million-8.43Upcoming Earnings
Analyst Downgrade
Unusual Options Activity
Generation Bio logo
GBIO
Generation Bio
1.9$20.92+0.3%$1.18 billionN/A-7.09
Endo International logo
ENDP
Endo International
1.7$4.92+0.6%$1.15 billion$2.90 billion12.30Unusual Options Activity
News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.63+1.6%$1.12 billionN/A-18.23Analyst Upgrade
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$5.58+0.4%$1.12 billion$132.30 million-19.93Upcoming Earnings
Precigen logo
PGEN
Precigen
1.7$5.40+3.0%$1.11 billion$103.18 million-7.11
NRXP
NRx Pharmaceuticals
1.0$23.02+28.5%$1.10 billionN/A0.00News Coverage
Gap Up
MannKind logo
MNKD
MannKind
1.4$4.42+1.4%$1.10 billion$65.14 million-17.00Analyst Upgrade
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.5$9.49+2.3%$1.09 billion$46.55 million-11.72
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$19.56+0.8%$1.09 billion$248.17 million34.32Upcoming Earnings
News Coverage
Olema Pharmaceuticals logo
OLMA
Olema Pharmaceuticals
1.8$26.18+4.9%$1.05 billionN/A-7.65Insider Selling
Short Interest Increase
News Coverage
This page was last updated on 7/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.